Biology:A20 cells

From HandWiki
Short description: Cell line

A20 cells, also called ATCC TIB-208, is a cell line originally derived from B-cell lymphoma in an old BALB/c mouse.[1] AT20 cells are BALB/c lymphoma cells derived from spontaneous reticulum cell neoplasm.[2] ATCC TIB-208 cells originated from B-cell lymphoma in the reticulum cell sarcoma of an elderly BALB/c mouse.[3] A20 cells are used in medical research such as drug screening or vaccine target selection.[4][5][6] A20 cells are also highly responsive to immunomodulatory antibodies, and are therefore used frequently in immunotherapy drug studies.[3]

References

  1. Kim, KJ; Kanellopoulos-Langevin, C; Merwin, RM; Sachs, DH; Asofsky, R (1979). "Establishment and characterization of BALB/c lymphoma lines with B cell properties.". Journal of Immunology 122 (2): 549–554. doi:10.4049/jimmunol.122.2.549. PMID 310843. 
  2. Priem, Dario; van Loo, Geert; Bertrand, Mathieu J. M. (2020-05-01). "A20 and Cell Death-driven Inflammation" (in en). Trends in Immunology 41 (5): 421–435. doi:10.1016/j.it.2020.03.001. ISSN 1471-4906. PMID 32241683. https://www.sciencedirect.com/science/article/pii/S1471490620300399. 
  3. 3.0 3.1 "A20: Modeling B cell lymphoma in mice". https://drugdevelopment.labcorp.com/industry-solutions/oncology/preclinical/tumor-spotlights/a20-modeling-b-cell-lymphoma-mice.html. 
  4. Meziane el, K; Bhattacharyya, T; Armstrong, AC; Qian, C; Hawkins, RE; Stern, PL; Dermime, S (2004-10-10). "Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.". International Journal of Cancer 111 (6): 910–920. doi:10.1002/ijc.20332. PMID 15300803. 
  5. Siegel, S; Wagner, A; Kabelitz, D; Marget, M; Coggin J, Jr; Barsoum, A; Rohrer, J; Schmitz, N et al. (2003-12-15). "Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.". Blood 102 (13): 4416–23. doi:10.1182/blood-2003-01-0198. PMID 12869512. 
  6. Siegel, S; Wagner, A; Schmitz, N; Zeis, M (2003). "Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.". British Journal of Haematology 122 (6): 911–4. doi:10.1046/j.1365-2141.2003.04535.x. PMID 12956760. 

External links